$LTRN News

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026

Lantern Pharma secures Taiwan clearances for Phase II NSCLC study

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering

Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development - Slideshow

Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET

Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas

Lantern Pharma Issued Notice Of Allowance From U.S. Patent And Trademark Office For Application Titled Method For Treating Blood Cancers

Lantern Pharma Q2 2026 Earnings Call: Complete Transcript

Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23

Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript

Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ...

Lantern Pharma Inc. 2026 Q2 - Results - Earnings Call Presentation

Lantern Pharma Inc. Q2 2026 Earnings Call Summary

Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Lantern Pharma Q2 EPS $(0.57) Misses $(0.38) Estimate

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET